MICROSPHERES FOR IMPROVED BIOAVAILABILITY

描述：研究人员提议开发纳米颗粒 用于治疗剂的可生物降解的聚合物口服给药系统 代表疏水性小分子、蛋白质和基因，并将 研究他们的理解，如他们的摘要所进一步描述的： 我们的项目专注于开发基于纳米颗粒的口服给药。 由可生物降解的聚合物组成的体系，用于有效地封装 并提高三种代表性药物的生物利用度和摄取率 来自当前研究最活跃领域的治疗剂：小 疏水分子(紫杉醇)、蛋白质(胰岛素)和基因。 尽管已经对前两个系统进行了大量研究，但 提高这些药物的口服生物利用度是一个挑战。不是 产品可以在市场上买到，特别是口腔 多肽和蛋白质的输送。最后一个系统是最具挑战性的 其一，因为在口头传递基因方面所做的工作很少。 “我们的假设是，如果我们成功地增强了对药物的摄取 纳米粒子，那么我们可能能够提高每种药物的生物利用度 潜在的毒品候选者。对于紫杉醇和胰岛素，我们将针对 增加系统的生物利用度，而对于质粒则是He的性质 增强可能是局部的，也可能是系统性的。

DESCRIPTION: The investigators propose to develop nanoparticulate biodegradable polymeric oral delivery systems for therapeutic agents representative of hydrophobic small molecules, proteins, and genes, and will study their uptake, as further described by their abstract: "Our project focuses on the development of nanoparticle-based, oral delivery systems, composed of biodegradable polymers, used to efficiently encapsulate and increase the bioavailability and uptake of three representative therapeutic agents from the most active fields of current research: small hydrophobic molecules (taxol), proteins (insulin) and genes. "Although much research has been performed with the first two systems, still there is a challenge to improve the oral bioavailability of these drugs. No product is commercially available on the market, particularly for the oral delivery of peptides and proteins. The last system is the most challenging one, since very little work has been done on oral delivery of genes. "Our hypothesis is that if we succeed in enhancing uptake of drug-loaded nanoparticles, then we may be able to enhance the bioavailability of each of the potential drug candidates. For taxol and insulin, we will target an increase in systemic bioavailability, while for plasmids the nature of he enhancement may be either local or systemic."